Cingulate Inc.
CINGAnalyst Consensus
Price Target Trend
Rating Trend
Recent Price Targets
Recent Rating Actions
| Firm | Action | Rating | Date |
|---|---|---|---|
| Roth Capital | maintain | Buy | Aug 24, 2026 |
| Ascendiant Capital | maintain | Buy | Aug 20, 2026 |
| Ascendiant Capital | maintain | Buy | Jun 8, 2026 |
| HC Wainwright & Co. | maintain | Buy | May 26, 2026 |
| Ascendiant Capital | maintain | Buy | Apr 8, 2026 |
| Roth Capital | maintain | Buy | Mar 23, 2026 |
| Ascendiant Capital | maintain | Buy | Dec 8, 2025 |
| Roth Capital | maintain | Buy | Nov 19, 2025 |
| Roth Capital | maintain | Buy | Oct 15, 2025 |
| Ascendiant Capital | maintain | Buy | Aug 22, 2025 |
| Ascendiant Capital | maintain | Buy | May 27, 2025 |
| Roth Capital | maintain | Buy | May 19, 2025 |
| Ascendiant Capital | maintain | Buy | Apr 21, 2025 |
| HC Wainwright & Co. | maintain | Buy | Mar 6, 2025 |
| HC Wainwright & Co. | maintain | Buy | Jan 30, 2025 |
| Maxim Group | upgrade | Hold →Buy | Nov 20, 2024 |
| HC Wainwright & Co. | maintain | Buy | Jan 5, 2024 |
| Laidlaw & Co. | downgrade | Buy →Hold | Dec 22, 2023 |
| Maxim Group | downgrade | Buy →Hold | Dec 19, 2023 |
| Maxim Group | downgrade | Buy →Hold | Dec 18, 2023 |
| HC Wainwright & Co. | maintain | Buy | Sep 25, 2023 |
| HC Wainwright & Co. | maintain | Buy | Jan 17, 2023 |
| Maxim Group | maintain | Buy | Nov 22, 2022 |
| Laidlaw & Co. | maintain | Buy | Jan 20, 2022 |
| Aegis Capital | maintain | Buy | Jan 11, 2022 |
Earnings History
Next report: Nov 12, 2026 · EPS est. $-0.48| Report Date | EPS Actual | EPS Est. | Revenue Actual | Revenue Est. |
|---|---|---|---|---|
| Aug 13, 2026 | $-0.45 | $-0.63 | — | $166.7K |
| May 14, 2026 | $-0.95 | $-0.53 | — | — |
| Mar 18, 2026 | $-0.84 | $-0.56 | — | — |
| Nov 13, 2025 | $-1.35 | $-0.80 | — | — |
| Aug 19, 2025 | $-1.09 | $-0.82 | — | — |
| May 8, 2025 | $-1.04 | $-1.00 | — | — |
| Mar 27, 2025 | $-1.80 | $-1.48 | — | — |
| Nov 7, 2024 | $-1.83 | $-2.22 | — | — |
News
Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma Chief Commercial Officer Bryan Downey Joins Panel Discussion on Reinventing the Launch Playbook for Small and Mid-Size Pharma
KANSAS CITY, Kan., Aug. 13, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended June 30, 2026, and provided a corporate update.
KANSAS CITY, Kan., Aug. 11, 2026 (GLOBE NEWSWIRE) -- Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company advancing next-generation pharmaceutical products through its proprietary Precision Timed Release™ (PTR™) drug delivery platform, today announced the publication of "Comparative Bioavailability of Trimodal CTx-1301 Versus Bimodal Dexmethylphenidate" in the peer-reviewed journal CNS Drugs.